#USA #New York #Actinium Pharmaceuticals #targeted radiotherapy #Sean Maenpaa

Actinium Pharmaceuticals Welcomes Sean Maenpaa as Senior Vice President of Business Development

On October 12, 2026, Actinium Pharmaceuticals, a renowned innovator in targeted radiotherapies, announced the appointment of Sean Maenpaa as the Senior Vice President of Business Development. With over two decades of experience in the oncology sector, Maenpaa is poised to significantly influence Actinium's business strategy. His past roles have equipped him with a robust understanding of radiopharmaceuticals, making him a well-suited leader for the company’s initiatives.

A Wealth of Experience

Before joining Actinium, Maenpaa led strategic business development efforts at several prestigious firms in the radiopharmaceutical field, including Bayer, Clovis Oncology, and Telix Pharmaceuticals. His extensive experience encompasses a wide range of areas—alpha and beta-emitting radiotherapies, diagnostic PET imaging, and the supply chain of medical isotopes. This diverse background is uncommon in the industry and positions Maenpaa uniquely within the field.

Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, remarked, "Sean is among the few executives with comprehensive experience across the entire radiopharmaceutical value chain. His expertise ranges from isotope supply and manufacturing to therapy strategies and commercial launches. He brings invaluable knowledge and connections that will help unlock the potential of our innovative pipeline."

Focus on Strategic Partnerships

In his new role, Maenpaa will focus on out-licensing, partnering, and strategic transactions to maximize Actinium's development pipeline. As interest from large pharmaceutical companies in targeted radiotherapies is rising, his experience and relationships in the industry will be crucial for the company's growth.

Maenpaa expressed enthusiasm for his new role, stating, "Actinium boasts one of the most comprehensive repositories of knowledge regarding Actinium-225 and targeted radiotherapies. I look forward to collaborating with our team to forge partnerships that leverage our robust clinical data and unique assets to enhance cancer treatments."

Notable Achievements

Maenpaa's career highlights include his tenure as Managing Director of Maenpaa Consulting LLC, where he provided strategic insights for oncology radiopharmaceutical developers. At BWXT Medical, he was the Vice President overseeing sales and development of medical radioisotope supplies exceeding $120 million. His success at Telix Pharmaceuticals saw a pivotal contribution in establishing a uro-oncology franchise, driving global sales of ILLUCCIX® to $320 million.

Previously, he also held significant roles at Clovis Oncology and Bayer AG, where he was instrumental in licensing initiatives and managed pivotal treatment assets in the rapidly evolving oncology landscape.

Committed to Innovation

Actinium Pharmaceuticals continues to focus on developing innovative therapies that improve patient outcomes. The company's pipeline encompasses several groundbreaking projects, including targeted treatments for hematologic malignancies and solid tumors. Their unique approach aims to enhance therapeutic efficacy while minimizing toxicity to healthy tissues.

Actinium's targeted radiotherapies are pivotal in advancing cancer treatment, showcasing their commitment to improving patient lives through science and innovation. With Maenpaa now at the helm of business development, Actinium aims to accelerate partnerships and broaden the impact of its cutting-edge therapies.

For more details about Actinium Pharmaceuticals and their innovative contributions to oncology, visit Actinium Pharmaceuticals.